Boehringer Ingelheim (PRIVATE.BOEHRINGER)

Overall impact
B (66)

Commentary

Boehringer Ingelheim is a strong overall performer. With a 'B' rating of 66.2 for overall impact (75th percentile compared to all companies), Boehringer Ingelheim ranks 21st out of 30 industry peers, behind Sanofi, Adynxx, Alimera Sciences and 17 others, and ahead of Heron Therapeutics, Aerie Pharmaceuticals, Tonix Pharmaceuticals and 6 others. On top material causes for Boehringer Ingelheim's industry (Pharmaceuticals & Biotech), Boehringer Ingelheim performs well in Disease Eradication (96.3 score), Child and Maternal Health (87.8), Sustainable Use of Water (90.7) and 2 other causes where it received an 'A' score and performs poorly in Accountable Institutions (0.0 score), Racial Justice and Civil Rights (36.3) and Accountable Institutions (0.0).
Impact
Cause PRIVATE.BOEHRINGER
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1885
Employees
44,036
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Share classes
PRIVATE.BOEHRINGER
Description
Our people are our strength. And, together with over 53,000 colleagues, we're creating the next breakthrough in the world of health and innovation for both humans and animals.
Material causes
Ethos considers the following causes material for Boehringer Ingelheim, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.